methyl 4-piperidin-4-yl>butanoate | 142355-82-6

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 4-piperidin-4-yl>butanoate
• 英文别名: tert-butyl 4-(4-methoxy-4-oxobutyl)piperidine-1-carboxylate；methyl 4-(N-BOC-piperidin-4-yl) butyrate
• CAS: 142355-82-6
• 化学式: C₁₅H₂₇NO₄
• 分子量: 285.384
• InChiKey: XEQCRPOWJVRXTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  354.8±15.0 °C(Predicted)
• 密度：
  1.036±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-piperidin-4-yl>butanoate 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 四溴化碳 、 硼烷 、 氢气 、 sodium hydride 、 sodium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 59.5h， 生成 盐酸替罗非班
  参考文献：
  名称：

  Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

  摘要：

  Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation. Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation. Compound 23m (L-700,462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of > 24 000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors. Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions of 0.1-10 mu g/kg/min of 23m in anesthetized dogs, with 10 mu g/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol. Platelet aggregatability returned rapidly after the termination of the 23m infusions. These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.

  DOI：

  10.1021/jm00042a007
• 作为产物：
  描述：

  N-Boc-4-哌啶乙醇 在 palladium on activated charcoal 草酰氯 、 氢气 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 1.83h， 生成 methyl 4-piperidin-4-yl>butanoate
  参考文献：
  名称：

  Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

  摘要：

  Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation. Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation. Compound 23m (L-700,462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of > 24 000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors. Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions of 0.1-10 mu g/kg/min of 23m in anesthetized dogs, with 10 mu g/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol. Platelet aggregatability returned rapidly after the termination of the 23m infusions. These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.

  DOI：

  10.1021/jm00042a007

文献信息

• [EN] PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS<br/>[FR] COMPOSES DE PIPERIDINYLE LIANT SELECTIVEMENT LES INTEGRINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004020435A1

  公开（公告）日：2004-03-11

  The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.

  这项发明涉及选择性结合整合素受体的式(I)和(II)的哌啶基化合物，以及治疗整合素介导的疾病的方法，其中W、R2、Z和q在申请中有描述。
• [EN] ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS D'ETHER D'ARYL ET D'HETEROARYLE EN TANT QU'AGONISTES DES RÉCEPTEURS Β X DU FOIE, COMPOSITIONS ET UTILISATION ASSOCIÉE
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068295A1

  公开（公告）日：2018-04-19

  Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  式(I)中的取代芳基和杂环芳基醚化合物及其药用盐，其中X、R1、R2、R3、L、R4、L1、Q和R5如本文所定义。这些化合物和含有其化合物的药用组合物可用作肝X-β受体(LXRβ)激动剂，并可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。
• Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05866685A1

  公开（公告）日：1999-02-02

  The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基酰基肽和伪肽，因此在预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、周围动脉疾病和弥散性血管内凝血等方面具有用途，以及用于在需要此类治疗的哺乳动物中预防或治疗血栓形成的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的药物组合物。
• Novel sulfonamide fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05292756A1

  公开（公告）日：1994-03-08

  A series of non-peptide derivatives of the formula ##STR1## that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.

  一系列非肽衍生物的化学式为 ##STR1##，它们是纤维蛋白原IIb/IIIa受体的拮抗剂，因此是有用的血小板抗聚集化合物，可用于预防和治疗由血栓形成引起的疾病。
• [EN] ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES<br/>[FR] PEPTIDES ET PSEUDOPEPTIDES A GROUPE AZACYCLOALKYLALCANOYLE AYANT DES PROPRIETES ANTITHROMBOTIQUES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：WO1995010295A1

  公开（公告）日：1995-04-20

  (EN) The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.(FR) La présente invention concerne des peptides ou pseudopeptides à groupe azacycloalkylalcanoyle qui inhibent l'agrégation plaquettaire et la formation de thrombus, ce qui les rend utiles dans la prévention et le traitement de thromboses que l'on rencontre dans des états pathologiques tels que l'infarctus du myocarde, les accidents cérébrovasculaires, les maladies vasculaires périphériques, et la coagulation intravasculaire disséminée. L'invention concerne également des méthodes de prévention ou de traitement de thromboses chez des mammifères nécessitant une telle thérapie, consistant à d'administrer une dose appropriée de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和假肽，因此可用于预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血，以及用于治疗需要此类治疗的哺乳动物的预防或治疗血栓形成的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。